Extracellular matrix remodelling that occurs in pancreatic ductal adenocarcinoma (PDAC) is considered a promoting factor of cancer growth, immune evasion and therapeutic resistance. Cancer-associated fibroblasts (CAFs) that constitute the dominant stromal population, arise primarily from activated pancreatic stellate cells and display remarkable functional heterogeneity, encompassing inflammatory iCAFs and contractile myCAFs. Although epithelial-stromal communication is central to PDAC biology, the upstream mechanisms that prime tumour cells toward CAF-Activating cells remain incompletely defined. The leukaemia inhibitory factor (LIF), a pleiotropic cytokine of the IL-6 family, is highly expressed in PDAC and has been implicated in tumour progression. However, the role of LIF and LIF receptor (LIFR):gp130 complex in promoting CAF activation is poorly defined. Here, we combined human PDAC transcriptomics, immunofluorescence and epithelial-stromal co-culture assays to define LIF-driven pro-CAF programs and evaluate their pharmacological reversibility. In PDAC cancer cells, MIAPaCa-2 cells, LIF induced a coordinated transcriptional network encompassing inflammatory mediators, paracrine fibroblast-activating signals and ECM/mechanotransductive modules, while repressing stromal-inhibitory genes. These signatures were recapitulated in PDAC tissues, where LIF expression directly correlated with CAF markers and with stromal remodelling genes. On this background, we have developed a novel steroidal LIFR antagonist, LRI310, and evaluate its effects on LIF:LIFR axis. Exposure of PDCA cell lines to LRI310 suppresses STAT3 activation and counteracts effects of LIF on proliferation and CAF-inducing transcriptional programs. Collectively, these findings identify LIF as an important epithelial driver of CAF-oriented transcriptional programs in PDAC and support the development of LIFR antagonism as a promising strategy to modulate the desmoplastic microenvironment.

LIFR antagonism reverses epithelial pro-CAF programs in pancreatic ductal adenocarcinoma / Giorgio, Cristina Di; Sette, Maria Rosaria; Sensini, Benedetta; Giannelli, Eleonora; Lachi, Ginevra; Marchianò, Silvia; Paniconi, Francesca; Massa, Carmen; Urbani, Ginevra; Gregorio, Rosa De; Sepe, Valentina; Monti, Maria Chiara; Moraca, Federica; Catalanotti, Bruno; Cartaginese, Fabio; Distrutti, Eleonora; Zampella, Angela; Biagioli, Michele; Fiorucci, Stefano. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 246:(2026), pp. 117707-117723. [10.1016/j.bcp.2026.117707]

LIFR antagonism reverses epithelial pro-CAF programs in pancreatic ductal adenocarcinoma

Gregorio, Rosa De;Sepe, Valentina;Monti, Maria Chiara;Moraca, Federica;Catalanotti, Bruno;Zampella, Angela;
2026

Abstract

Extracellular matrix remodelling that occurs in pancreatic ductal adenocarcinoma (PDAC) is considered a promoting factor of cancer growth, immune evasion and therapeutic resistance. Cancer-associated fibroblasts (CAFs) that constitute the dominant stromal population, arise primarily from activated pancreatic stellate cells and display remarkable functional heterogeneity, encompassing inflammatory iCAFs and contractile myCAFs. Although epithelial-stromal communication is central to PDAC biology, the upstream mechanisms that prime tumour cells toward CAF-Activating cells remain incompletely defined. The leukaemia inhibitory factor (LIF), a pleiotropic cytokine of the IL-6 family, is highly expressed in PDAC and has been implicated in tumour progression. However, the role of LIF and LIF receptor (LIFR):gp130 complex in promoting CAF activation is poorly defined. Here, we combined human PDAC transcriptomics, immunofluorescence and epithelial-stromal co-culture assays to define LIF-driven pro-CAF programs and evaluate their pharmacological reversibility. In PDAC cancer cells, MIAPaCa-2 cells, LIF induced a coordinated transcriptional network encompassing inflammatory mediators, paracrine fibroblast-activating signals and ECM/mechanotransductive modules, while repressing stromal-inhibitory genes. These signatures were recapitulated in PDAC tissues, where LIF expression directly correlated with CAF markers and with stromal remodelling genes. On this background, we have developed a novel steroidal LIFR antagonist, LRI310, and evaluate its effects on LIF:LIFR axis. Exposure of PDCA cell lines to LRI310 suppresses STAT3 activation and counteracts effects of LIF on proliferation and CAF-inducing transcriptional programs. Collectively, these findings identify LIF as an important epithelial driver of CAF-oriented transcriptional programs in PDAC and support the development of LIFR antagonism as a promising strategy to modulate the desmoplastic microenvironment.
2026
LIFR antagonism reverses epithelial pro-CAF programs in pancreatic ductal adenocarcinoma / Giorgio, Cristina Di; Sette, Maria Rosaria; Sensini, Benedetta; Giannelli, Eleonora; Lachi, Ginevra; Marchianò, Silvia; Paniconi, Francesca; Massa, Carmen; Urbani, Ginevra; Gregorio, Rosa De; Sepe, Valentina; Monti, Maria Chiara; Moraca, Federica; Catalanotti, Bruno; Cartaginese, Fabio; Distrutti, Eleonora; Zampella, Angela; Biagioli, Michele; Fiorucci, Stefano. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 246:(2026), pp. 117707-117723. [10.1016/j.bcp.2026.117707]
File in questo prodotto:
File Dimensione Formato  
149_BP_2026.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 14.47 MB
Formato Adobe PDF
14.47 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1026627
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact